Blog
From bedside to bench and back again: Review of โCuredโ by Nathalia Holt
In HIV and many other areas of biopharma, there are no shortcuts - sometimes science progresses a single patient at a time.
Baby biotech grows up: Review of "The Antidote" by Barry Werth
How do you build a drug company? Barry Werth continues the story of Vertex's birth and teenage years that he started with "Billion Dollar Molecule".
"Saving the winners" to improve pharma R&D
Adaptive trials could be a way to improve the pharma industry's dismal R&D success rates.
The future of pharma sales reps
Can you think of a good reason to have a Pharma sales force? Neither can I.
Academic medical centers and transparency of trial results
There's plenty of work to do to promote clinical data transparency. AMCs need to do their part.
Cancer R&D's tenuous value chain
To succeed in oncology drug development, Pharma execs need new approaches to clinical trials, diagnostics and pricing.
In defense of pharma forecasting
The problem isn't with Pharma forecasts โ it's with how they're communicated and used in decision-making.
A victim of his success: Malcolm Gladwell's "David and Goliath"
Let's get one thing out of the way: if you're a Gladwell hater, this book will not change your mind.
Clinical trial transparency - The road ahead
There's lots of work to do in trial registration, results dissemination, and data access. Let's get cracking.
The Mystery of McKinsey: Review of "The Firm" by Duff McDonald
Almost 100 years since its founding, we're still no closer to answering the age-old question about McKinsey: Are they worth it?